These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 10805101)

  • 21. Multidrug resistance: molecular mechanisms and clinical relevance.
    Ling V
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP.
    Roller A; Bähr OR; Streffer J; Winter S; Heneka M; Deininger M; Meyermann R; Naumann U; Gulbins E; Weller M
    Biochem Biophys Res Commun; 1999 Jun; 259(3):600-5. PubMed ID: 10364464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
    Lopes EC; Scolnik M; Alvarez E; Hajos SE
    Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
    Chao CC
    FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
    Huet S; Schott B; Robert J
    Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
    Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
    Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
    Ashmore SM; Thomas DG; Darling JL
    Anticancer Drugs; 1999 Nov; 10(10):861-72. PubMed ID: 10630353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative.
    Méndez-Vidal C; Quesada AR
    Cancer Lett; 1998 Oct; 132(1-2):45-50. PubMed ID: 10397452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
    Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
    Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
    Kaaijk P; Troost D; de Boer OJ; Van Amstel P; Bakker PJ; Leenstra S; Bosch DA
    Br J Cancer; 1996 Jul; 74(2):187-93. PubMed ID: 8688320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
    Vilpo J; Koski T; Vilpo L
    Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
    Stein U; Walther W; Shoemaker RH
    Br J Cancer; 1996 Nov; 74(9):1384-91. PubMed ID: 8912533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
    Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
    Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole.
    Jansen WJ; Pinedo HM; Kuiper CM; Lincke C; Bamberger U; Heckel A; Boven E
    Ann Oncol; 1994 Oct; 5(8):733-9. PubMed ID: 7826906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
    Adams DJ; Knick VC
    Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
    Liang BC
    J Neurooncol; 1996 Aug; 29(2):149-55. PubMed ID: 8858520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines.
    Declèves X; Fajac A; Lehmann-Che J; Tardy M; Mercier C; Hurbain I; Laplanche JL; Bernaudin JF; Scherrmann JM
    Int J Cancer; 2002 Mar; 98(2):173-80. PubMed ID: 11857404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
    Jonsson B; Nilsson K; Nygren P; Larsson R
    Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.